Dual pathway inhibition in patients with atherosclerotic disease: pharmacodynamic considerations and clinical implications
Introduction The persistence of elevated rates of ischemic recurrences despite the use of
antiplatelet therapy among patients with atherosclerotic disease together with the …
antiplatelet therapy among patients with atherosclerotic disease together with the …
Pharmacodynamic profiles of dual-pathway inhibition with or without clopidogrel versus dual antiplatelet therapy in patients with atherosclerotic disease
Aim Inhibition of thrombin-mediated signaling processes using a vascular dose of
rivaroxaban in adjunct to antiplatelet therapy, known as dual-pathway inhibition (DPI) …
rivaroxaban in adjunct to antiplatelet therapy, known as dual-pathway inhibition (DPI) …
Dual pathway inhibition for atherosclerotic cardiovascular disease: Recent advances
S Carlin, TAC de Vries, A Budaj… - … Polska (Polish Heart …, 2022 - journals.viamedica.pl
Atherosclerotic cardiovascular disease (ASCVD), which includes coronary artery disease
(CAD), cerebrovascular disease, and peripheral arterial disease (PAD) is associated with …
(CAD), cerebrovascular disease, and peripheral arterial disease (PAD) is associated with …
Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet …
Aims Dual pathway inhibition (DPI) by adding a vascular dose of rivaroxaban to a single
antiplatelet agent has emerged as a promising antithrombotic strategy. However, in most …
antiplatelet agent has emerged as a promising antithrombotic strategy. However, in most …
[HTML][HTML] Dual pathway inhibition for vascular protection in patients with atherosclerotic disease: rationale and review of the evidence
JI Weitz, DJ Angiolillo, T Geisler… - Thrombosis and …, 2020 - thieme-connect.com
Despite advances in secondary prevention strategies in patients with cardiovascular
disease, the residual risk of recurrent atherothrombotic events remains high. Dual …
disease, the residual risk of recurrent atherothrombotic events remains high. Dual …
Efficacy and safety of dual-pathway inhibition in patients with cardiovascular disease: a meta-analysis of 49 802 patients from 7 randomized trials
M Galli, D Capodanno, S Benenati… - European Heart …, 2022 - academic.oup.com
Aims Low-dose (LD) direct oral anticoagulants (DOACs) in adjunct to antiplatelet therapy,
known as dual-pathway inhibition (DPI), have been tested to prevent ischaemic events in …
known as dual-pathway inhibition (DPI), have been tested to prevent ischaemic events in …
Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The …
Aims To determine the characteristics of patients with coronary artery disease (CAD),
peripheral artery disease (PAD), or both, initiating dual pathway inhibition (DPI) using …
peripheral artery disease (PAD), or both, initiating dual pathway inhibition (DPI) using …
Low-dose rivaroxaban: can cardiovascular events be reduced?
L De Luca - European Heart Journal Supplements, 2023 - academic.oup.com
Despite available effective guideline-based preventive therapies, patients with vascular
diseases remain at high-risk of recurrent ischaemic events. Novel therapeutic strategies are …
diseases remain at high-risk of recurrent ischaemic events. Novel therapeutic strategies are …
Synergy of dual pathway inhibition in chronic cardiovascular disease: lessons from the COMPASS trial
M Coppens, JI Weitz, JWA Eikelboom - Circulation research, 2019 - Am Heart Assoc
Although acetylsalicylic acid is of proven benefit for secondary prevention in patients with
cardiovascular disease, the risk of recurrent ischemic events remains high. Intensification of …
cardiovascular disease, the risk of recurrent ischemic events remains high. Intensification of …
[HTML][HTML] The Net Clinical Outcome of Dual-Pathway Inhibition in Clinical Practice: The “Xarelto plus Acetylsalicylic Acid: Treatment Patterns and Outcomes in Patients …
A Breitenstein, A Gay, K Vogtländer, KAA Fox… - Journal of Clinical …, 2024 - mdpi.com
Background: In the COMPASS trial, the combination of acetylsalicylic acid (ASA) plus 2.5 mg
rivaroxaban twice daily (dual-pathway inhibition, DPI) has been shown to be superior to ASA …
rivaroxaban twice daily (dual-pathway inhibition, DPI) has been shown to be superior to ASA …
相关搜索
- dual pathway inhibition
- pathway inhibition clinical implications
- pathway inhibition antiplatelet therapy
- pathway inhibition vascular dose
- pathway inhibition clinical practice
- pathway inhibition rivaroxaban or aspirin
- pathway inhibition vascular protection
- pathway inhibition inflammatory biomarkers
- pathway inhibition platelet p2y12
- pathway inhibition xatoa registry
- pharmacodynamic considerations clinical implications
- antiplatelet therapy vascular dose
- antiplatelet therapy pharmacodynamic profiles
- antiplatelet therapy rivaroxaban or aspirin
- antiplatelet therapy platelet p2y12
- rivaroxaban or aspirin vascular dose